| Filed On | Filing |
|---|---|
| 13 Nov 2026 | DEFA14A |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Proposed share exchange transaction expected to create a multi-indication clinical stage company focused on targeting neutrophil extracellular traps (NETs) |
| 12 Nov 2026 | FORM 10-Q FOR SEP 2026 |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026 |
| 18 Sep 2026 | SCHEDULE 13G |
| 16 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
______________________________________________________________________________ |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition
Expanded collaborative research initiatives reinforce the Company's long-term |
| 06 Aug 2026 | FORM 10-Q FOR JUN 2026 |
| 29 May 2026 | SCHEDULE 13G |
| 14 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Advancements across investigator-initiated studies, translational research and |
| 12 May 2026 | QUARTERLY REPORT FOR MARCH 2026 |
| 24 Apr 2026 | FORM 10-K FOR DEC 2025 AMENDMENT 1 |
| 24 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Xenetic Biosciences, Inc. (the “Company”) hereby grants the following shares of restricted stock (“Restricted Stock”) pursuant to its Amended and Restated Equity Incentive Plan (as may be amended, the “Plan”). The terms of the grant are ... |
| 23 Apr 2026 |
Form 4: Parslow James F, Interim CEO and CFO
Received 100,000 shares as a grant or award |
| 13 Mar 2026 |
8-K: Results of Operations and Financial Condition
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers |
| 12 Mar 2026 | FORM 10-K FOR DEC 2025 |
| 12 Feb 2026 | SCHEDULE 13G |
| 09 Jan 2026 |
8-K: Other Events
On December 11, 2025, Xenetic Biosciences, Inc. (the “Company”) announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for December 11, 2025, had been adjourned until January 8, 2026 in order ... |
Loading...